Hormonal · Lifecycle Market Map

Hormonal Health

37 companies across the full female hormonal lifecycle — puberty, PCOS, perimenopause, menopause — mapped by infrastructure lane and funding stage. The working stack: at-home diagnostics, novel therapeutics, marketed pharma, devices, virtual care, and consumer wellness.

Jump to the map Open directory

Companies

$1029M

Disclosed funding

Clinical / pipeline

Commercial

Countries

Stage buckets

Capital concentration

Where the category sits on the maturity curve

Stage distribution across the indexed cohort. Each bar segment is a company count, ordered from pre-seed to public.

Pre-seed6

Seed3

Series A9

Series B3

Series C+1

Growth10

Public / Marketed5

The map

Companies by infrastructure lane

Infrastructure lane × stage. Cards ordered by maturity then disclosed funding within each row.

Diagnostics

5 companies

Mira Care

Growth

Quantitative hormonal health monitoring across all life stages

USA

Hertility

Series A

Female hormone and fertility health testing

UK$16.3M

Oova

Series A

At-home quantitative hormone testing; PCOS and fertility monitoring

USA$10.3M

Inito

Series A

4-hormone at-home fertility monitor; designed for irregular cycles including PCOS

India / USA$6M

Hormona

Seed

At-home urine hormone testing + AI-driven cycle tracking and insights

UK / Sweden$6.7M

Therapeutics

4 companies

Spruce Biosciences

Public / Marketed

Congenital adrenal hyperplasia (CAH – affects puberty onset) and PCOS with adrenal androgen excess

USA$200M

Comanche Biopharma

Series B

Preeclampsia treatment (serious pregnancy complication) – NOT menopause

USA$136M

May Health (fka AblaCare)

Series B

PCOS-related infertility: ovarian rebalancing to restore natural ovulation

France$25M

ReproNovo

Series A

Reproductive medicine: male and female infertility; uterine health (adenomyosis)

Switzerland / Denmark$65M

Pharma

4 companies

Astellas (Veozah/Veoza)

Public / Marketed

First non-hormonal treatment for menopausal vasomotor symptoms (hot flashes/night sweats)

Japan

Bayer (Lynkuet/elinzanetant)

Public / Marketed

NK3 receptor antagonist for menopausal vasomotor symptoms; rival to Veozah

Germany

Gedeon Richter (Ryeqo)

Public / Marketed

Hormonal pill for endometriosis AND menopause VMS (dual indication)

Hungary

Pfizer (Myfembree)

Public / Marketed

Relugolix combination for menopause VMS and endometriosis

USA

Devices

3 companies

Oura

Growth

Smart ring for health tracking; perimenopause research partnership

Finland / USA$200M

Embr Labs

Growth

Wearable thermal therapy for menopausal hot flashes

USA

Amira / Grace

Series A

Wearable predicting and preventing hot flashes

Unknown

Digital Health

16 companies

Girlology

Growth

Puberty education for girls and mothers

USA

Elektra Health

Growth

Evidence-based menopause and perimenopause care; health plan innovation

USA

Gennev

Growth

Menopause healthcare and community platform

USA

Evela

Growth

Menopause care distributed via employers as workplace benefit

HerMD

Growth

Whole-person menopause and sexual health care

USA

Winona

Growth

Menopause HRT online prescriptions; bioidentical hormones

USA

Midi Health

Series C+

Virtual clinic for perimenopause and menopause; insurance-covered specialist care

USA$254M

Allara Health

Series B

Virtual care for PCOS, endometriosis, hypothyroidism, hormonal conditions

USA$38.5M

Evernow

Series A

Perimenopause and menopause telehealth + HRT delivery

USA$52.5M

Alloy Women's Health

Series A

Online menopause and perimenopause treatment

USA$16M

Stella

Series A

Perimenopause and menopause holistic virtual care

USA

Peppy

Series A

Employee menopause, fertility, and musculoskeletal health platform

Ove Care

Seed

Puberty and first period education ages 9–17

Luna

Pre-seed

Teen girl health and puberty education (ages 13–19)

Ashmi Health

Pre-seed

AI-driven hormonal health management app for PCOS

USA

NNABI

Pre-seed

Early perimenopause preparation and education

Unknown

Wellness & Consumer

5 companies

Stripes Beauty

Growth

Menopause-focused skincare and wellness brand

USA

MyOva

Seed

PCOS wellness supplements and education

DITTO Daily

Pre-seed

All-in-one cycle supplement for hormonal symptoms

UK$1.7M

Valerie

Pre-seed

Perimenopause-targeted supplements

UK$0.65M

Cloudstate

Pre-seed

Puberty-stage girls' adaptive bra and apparel

USA

Signals

Recent funding & catalysts

Midi Health Digital Health
Series D · $100M · Feb 2026
Advance Venture Partners (Series C lead); Emerson Collective; GV; Felicis; Memorial Hermann; Anne Wojcicki; Amy Schumer; Tory Burch
$254M total
ReproNovo Therapeutics
Series A · $65M · May 2025
Jeito Capital (lead); AXA IM Alts (co-lead); M Ventures (founding); Ysios Capital; ALSA Ventures
$65M total
Allara Health Digital Health
Series B · $26M · Jan 2025
Index Ventures (lead); GV (Google Ventures); Great Oaks VC; Humbition
$38.5M total
Hertility Diagnostics
Series A · Undisclosed · May 2025
Various UK/EU VCs
$16.3M total
Hormona Diagnostics
Seed · $6.6M (£5M) · May 2025
Voima Ventures (lead); SuperNode Global
$6.7M total

All companies — sortable & filterable

Company	Lane	Stage	HQ	Funding ↓	Latest	Status
Midi Health Virtual clinic for perimenopause and menopause; insurance-covered specialist care	Digital Health	Series C+	USA (Los Altos CA)	$254M	Feb 2026	Commercial – unicorn ($1B+ valuation Feb 2026); 230,000+ patients; all 50 states
Spruce Biosciences Congenital adrenal hyperplasia (CAH – affects puberty onset) and PCOS with adrenal androgen excess	Therapeutics	Public / Marketed	USA (South San Francisco CA)	$200M	N/A	Marketed products pipeline: Phase 3 adult CAH; Phase 2 pediatric CAH; Phase 2 PCOS data at ENDO 2024
Oura Smart ring for health tracking; perimenopause research partnership	Devices	Growth	Finland / USA (Oulu, Finland)	$200M	Various	Commercial – peri-specific features in development 2025
Comanche Biopharma Preeclampsia treatment (serious pregnancy complication) – NOT menopause	Therapeutics	Series B	USA (Concord MA)	$136M	Jan 2024	Phase 2 clinical development for preeclampsia
ReproNovo Reproductive medicine: male and female infertility; uterine health (adenomyosis)	Therapeutics	Series A	Switzerland / Denmark (Lausanne / Copenhagen)	$65M	May 2025	Phase 2 clinical trials ongoing
Evernow Perimenopause and menopause telehealth + HRT delivery	Digital Health	Series A	USA (San Francisco CA)	$52.5M	Apr 2022 (confirmed round)	Commercial – Clearblue partnership Jan 2025; Talkspace partnership Dec 2023
Allara Health Virtual care for PCOS, endometriosis, hypothyroidism, hormonal conditions	Digital Health	Series B	USA (New York NY)	$38.5M	Jan 2025	Commercial – 4x revenue growth 2024; nationwide all 50 states
May Health (fka AblaCare) PCOS-related infertility: ovarian rebalancing to restore natural ovulation	Therapeutics	Series B	France (Paris)	$25M	May 2024	Phase 2/3 clinical studies ongoing
Hertility Female hormone and fertility health testing	Diagnostics	Series A	UK (London)	$16.3M	May 2025	Commercial
Alloy Women's Health Online menopause and perimenopause treatment	Digital Health	Series A	USA (New York NY)	$16M	2024	Commercial – nationwide US
Oova At-home quantitative hormone testing; PCOS and fertility monitoring	Diagnostics	Series A	USA (New York NY)	$10.3M	2023	Commercial
Hormona At-home urine hormone testing + AI-driven cycle tracking and insights	Diagnostics	Seed	UK / Sweden (London / Stockholm)	$6.7M	May 2025	Commercial – 2M+ data points; 185+ countries; SpaceX partnership
Inito 4-hormone at-home fertility monitor; designed for irregular cycles including PCOS	Diagnostics	Series A	India / USA (Bangalore / USA)	$6M	2023	Commercial
DITTO Daily All-in-one cycle supplement for hormonal symptoms	Wellness & Consumer	Pre-seed	UK (London)	$1.7M	Aug 2025	Early commercial – CES 2026 Innovation Award Honoree
Valerie Perimenopause-targeted supplements	Wellness & Consumer	Pre-seed	UK (London)	$0.65M	May 2025	Early commercial
Luna Teen girl health and puberty education (ages 13–19)	Digital Health	Pre-seed	UK (London)	—	2023	Commercial – launched 2024
Ove Care Puberty and first period education ages 9–17	Digital Health	Seed	UK	—	2024	Commercial – launched Nov 2024
Girlology Puberty education for girls and mothers	Digital Health	Growth	USA	—	N/A	Commercial – long-established
Cloudstate Puberty-stage girls' adaptive bra and apparel	Wellness & Consumer	Pre-seed	USA (Boston MA)	—	2025	Launching 2025
Mira Care Quantitative hormonal health monitoring across all life stages	Diagnostics	Growth	USA (San Francisco CA)	—	Ongoing	Commercial – Oura integration 2025; CES 2026 Innovation Award Honoree
Ashmi Health AI-driven hormonal health management app for PCOS	Digital Health	Pre-seed	USA (Boston MA)	—	Unknown	Early / pilot stage
MyOva PCOS wellness supplements and education	Wellness & Consumer	Seed	UK	—	N/A	Commercial – DTC
Elektra Health Evidence-based menopause and perimenopause care; health plan innovation	Digital Health	Growth	USA	—	Unknown	Commercial; HelloMeno ACA plan launched Jan 2026
Stella Perimenopause and menopause holistic virtual care	Digital Health	Series A	USA	—	Unknown	Commercial
Gennev Menopause healthcare and community platform	Digital Health	Growth	USA	—	Unknown	Commercial – one of earliest dedicated menopause telehealth platforms
Embr Labs Wearable thermal therapy for menopausal hot flashes	Devices	Growth	USA	—	Unknown	Commercial – market pioneer in VMS wearables
Amira / Grace Wearable predicting and preventing hot flashes	Devices	Series A	Unknown	—	2024	Launched 2024
NNABI Early perimenopause preparation and education	Digital Health	Pre-seed	Unknown	—	2024	Launched 2024
Evela Menopause care distributed via employers as workplace benefit	Digital Health	Growth	UK	—	2025	Commercial – B2B employer model
Peppy Employee menopause, fertility, and musculoskeletal health platform	Digital Health	Series A	UK (London)	—	Various	Commercial – enterprise focus
Stripes Beauty Menopause-focused skincare and wellness brand	Wellness & Consumer	Growth	USA	—	Unknown	Commercial
Astellas (Veozah/Veoza) First non-hormonal treatment for menopausal vasomotor symptoms (hot flashes/night sweats)	Pharma	Public / Marketed	Japan (Tokyo)	—	N/A	Marketed: US FDA approved May 2023 (Veozah); EU EC approved Dec 2023 (Veoza). FY2024 revenue ¥33.8B (~$220M). FY2025 target ¥50B (~$330M). Black box warning for liver toxicity.
Bayer (Lynkuet/elinzanetant) NK3 receptor antagonist for menopausal vasomotor symptoms; rival to Veozah	Pharma	Public / Marketed	Germany (Leverkusen)	—	N/A	FDA approved Oct 2025. EU filing underway. Acquired via KaNDy Therapeutics ($875M acquisition, 2020). Peak sales forecast $1B+.
Gedeon Richter (Ryeqo) Hormonal pill for endometriosis AND menopause VMS (dual indication)	Pharma	Public / Marketed	Hungary (Budapest)	—	N/A	EU approved; NHS England approved Mar 2025. Consolidated group sales HUF 928.96B in 2025 (+8.3% YoY). Acquired Celmatix portfolio Mar 2026.
Pfizer (Myfembree) Relugolix combination for menopause VMS and endometriosis	Pharma	Public / Marketed	USA (New York NY)	—	N/A	Marketed US – FDA approved. Co-developed with Myovant Sciences (acquired by Pfizer/Sumitomo 2023).
HerMD Whole-person menopause and sexual health care	Digital Health	Growth	USA	—	Unknown	Commercial
Winona Menopause HRT online prescriptions; bioidentical hormones	Digital Health	Growth	USA	—	Unknown	Commercial

37 of 37

Analyst POV

Where the white space is

Where capital sits. Two extremes dominate: marketed pharma (Astellas, Bayer, Pfizer, Gedeon Richter) at one end, and a long pre-seed / seed tail of digital-first menopause and PCOS care at the other. Series B and C are thin — the funding gap is what stops digital winners from reaching pharma-scale distribution.

Where the white space is. Non-hormonal therapeutics for PCOS and perimenopause remain the largest unsolved problem. At-home quantitative hormone diagnostics (Oova, Mira, Hormona, Hertility, Inito) are converging — winner-takes-most depends on payer coverage and integration with the GLP-1 wave.

What to watch. Veozah/Veoza (Astellas) and Lynkuet (Bayer) commercial ramp; Spruce Phase 2 PCOS readout; Midi Health's Series C dynamics; and whether any of the at-home diagnostic players land an insurer.

As of 2026-06-12 · 37 companies · The Index

Back to Hormonal